Mefloquine for multidrug-resistant malaria.
Luxemburger
C
C
Nosten
F
F
ter Kuiile
F
F
Frejacques
L
L
Chongsuphajaisiddhi
T
T
White
N J
NJ
D000818:Animals; D000962:Antimalarials / Q000009:adverse effects*; D004338:Drug Combinations; D004351:Drug Resistance; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000517:prevention & control; D015767:Mefloquine / Q000009:adverse effects / Q000031:analogs & derivatives*; D010963:Plasmodium falciparum / Q000187:drug effects*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D011739:Pyrimethamine / Q000009:adverse effects*; D012036:Refugees; D013413:Sulfadoxine / Q000009:adverse effects*; D000096926:Benzenesulfonamides
D000962:Antimalarials; D004338:Drug Combinations; D015767:Mefloquine; D011739:Pyrimethamine; D013413:Sulfadoxine; C046846:mefloquine-sulfadoxine-pyrimethamine; D000096926:Benzenesulfonamides